Genetic or pharmacologic inhibition of KAT6A enhanced ovarian cancer cell response to cisplatin, suggesting that KAT6A inhibition can sensitize ovarian cancer cells to platinum-based chemotherapeutics. This evidence concerns the gene KAT6A and ovarian carcinoma.